Vaginal cancer

The Inner Circle acknowledges Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member

Retrieved on: 
Thursday, March 7, 2024
Theta, Overlook Medical Center, Woman, Professional, Inner circle, Doctor of Philosophy, Multimedia, MD, Georgetown University, Education, Immunotherapy, Pathology, Thomas Jefferson University, Uterine cancer, ABOG, Parent, Principal investigator, Radiation, National Cancer Institute, Women's studies, Gynecologic Oncology (journal), Health, FACOG, Oncology nursing, Brown University, Vaginal cancer, Ovarian cancer, Associate, Gestational trophoblastic disease, Women's health, Biology, Mount Sinai School, Estate (law), Delta Sigma, Research, Carol, Medication

CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies.
  • She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers.

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

Retrieved on: 
Wednesday, March 29, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histology, Hepatocellular carcinoma, Cohort, DOR, RECIST, Carcinoma, Head, Vaginal cancer, Patient, Division, Mesothelioma, Immunohistochemistry, NYSE, Prostate cancer, MMR, Glomus tumor, Oxaliplatin, MRK, Toxicity, Research, Brain, Nephritis, Merck & Co., Sarcoma, HIV disease progression rates, Cervical cancer, Polymerase chain reaction, MSI, Memorial Sloan Kettering Cancer Center, MSI-H, Pancreatic cancer, Hepatitis, Vulvar cancer, Cancer, Pneumonitis, Bladder cancer, Cholangiocarcinoma, Immunotherapy, Autoimmune disease, Irinotecan, Testicular cancer, Ovarian cancer, Thyroid cancer, ORR, Hematopoietic stem cell transplantation, Anal cancer, Colitis, Endometrial cancer, Immunosuppression, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Breast cancer, Pharmaceutical industry, Vaccine, Merck

This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.

Key Points: 
  • This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • Patients were either prospectively enrolled with MSI-H/dMMR tumors (Cohort K) or retrospectively identified in one of 10 solid tumor cohorts (Cohorts A-J).
  • In KEYNOTE-158 and KEYNOTE-164, the median duration of exposure to KEYTRUDA was 6.2 months (range, 1 day to 53.5 months).

Pap Test Market is expected to display a steady growth of 11.4% due to the rise in the number of disease-causing HPV cases| UnivDatos Market Insights

Retrieved on: 
Friday, March 17, 2023
Papanikolaou, COVID-19, QIAGEN, Probability, PAP, Liquid-based cytology, Hospital, Infection, Cervical cancer, Shock, Woman, Research, Cell, Inflammation, Pap test, Vaginal cancer, Thermo Fisher Scientific, Laboratory, Automation, Cancer, HPV, Clifton Springs Hospital & Clinic, Diagnosis, Mortality, American Cancer Society, AI, PCR, Female, BD, Disease, Birth control, Pharmaceutical industry, NOIDA, Others

The pap test market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The pap test market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.
  • This innovative report makes use of several analyses to get a closer outlook on the pap test market.
  • The pap test market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the pap test market at the global and regional levels.

Pap Test Market is expected to display a steady growth of 11.4% due to the rise in the number of disease-causing HPV cases| UnivDatos Market Insights

Retrieved on: 
Friday, March 17, 2023
Papanikolaou, COVID-19, QIAGEN, Probability, PAP, Liquid-based cytology, Hospital, Infection, Cervical cancer, Shock, Woman, Research, Cell, Inflammation, Pap test, Vaginal cancer, Thermo Fisher Scientific, Laboratory, Automation, Cancer, HPV, Clifton Springs Hospital & Clinic, Diagnosis, Mortality, American Cancer Society, AI, PCR, Female, BD, Disease, Birth control, Pharmaceutical industry, NOIDA, Others

The pap test market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The pap test market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.
  • This innovative report makes use of several analyses to get a closer outlook on the pap test market.
  • The pap test market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the pap test market at the global and regional levels.

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

Retrieved on: 
Thursday, January 19, 2023
Research, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, HPV-positive oropharyngeal cancer, HPV, B cell, Anal cancer, Heart, Safety, Gustave Roussy, Poly, Korea Disease Control and Prevention Agency, Cervical cancer, Partnership, Immune system, Patient, Cancer, Head, CDC, Vaginal cancer, Progression-free survival, Vaccine

Several exploratory objectives are also planned to estimate progression-free survival and overall survival.

Key Points: 
  • Several exploratory objectives are also planned to estimate progression-free survival and overall survival.
  • It represents a bridge between basic research and clinical research designed to accelerate innovation for the benefit of patients.
  • Together with Gustave Roussy, we look forward to making what we hope will be a major contribution to the treatment of HPV related cancers".
  • We hope that this first project will be inaugural of a long-standing and synergistic collaboration between LinKinVax and Gustave Roussy".

The Worldwide HPV Testing and Pap Test Industry is Projected to Reach $9.2 Billion by 2027: Rising HPV Cases and Subsequent Increase in Cervical Cancer Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Infectious Diseases, Health, Oncology, Medical Devices, HPV, Laboratory, Papilloma, Vaginal cancer, Pap test, Cervical cancer, Growth, PAP, Cancer, USD, Vaccine, Hospital

The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period
    The HPV testing and Pap test market is segmented into HPV testing and Pap test.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.
  • The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period
    The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening.

The Worldwide Cytology and HPV Testing Industry is Expected to Reach $14.9 Billion by 2027: Increasing Awareness of Cervical Cancer Screening Programs Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Infectious Diseases, Pharmaceutical, Health, Ansoff Matrix, Clifton Springs Hospital & Clinic, SWOT, Papilloma, Product type, USD, Hospital, Porter's five forces analysis, Risk, Growth, Impact, Cervical cancer, Investment, Laboratory, Vaginal cancer, Competitive analysis, COVID-19, PCR, Emotion, HPV, Observation, Market development, Instrument, Geography, Nursing care plan, Vaccine, Marketing, Risk management, Retail, Pharmaceutical industry, Application, Immunoassay

The report presents a detailed Ansoff matrix analysis for the Global Cytology and HPV Testing Market.

Key Points: 
  • The report presents a detailed Ansoff matrix analysis for the Global Cytology and HPV Testing Market.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
  • The report offers a comprehensive evaluation of the Global Cytology and HPV Testing Market.
  • By Product Type, the market is classified into PCR, Immunodiagnostics, and Other
    By Application, the market is classified into Cervical Cancer Screening and Vaginal Cancer Screening.

Global HPV Testing and Pap Test Market Report 2022 to 2027: Innovative Improvements in HPV Tests Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
General Health, Health, Oncology, PAP, Laboratory, Cancer, Vaginal cancer, HPV, Pap test, USD, Growth, Cervical cancer, Papilloma, Vaccine, Hospital

The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period
    The HPV testing and Pap test market is segmented into HPV testing and Pap test.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.

The Foundation Assar Gabrielssons fund scholarship recipients 2022 appointed: AB Volvo

Retrieved on: 
Friday, May 13, 2022
Cancer, Volvo, Knowledge, Nasdaq Stockholm, EUR, Patient, Motivation, Solution, PI3K, SEK, University of Gothenburg, Research, Vaginal cancer, Stammen, Sahlgrenska University Hospital, University, Senior advisor, Diagnosis, Pharmaceutical industry, Motor vehicle

The scholarship recipients, who both do research at the University of Gothenburg, are rewarded with SEK 100,000 each, which is paid to the Sahlgrenska Academy at the University of Gothenburg as extra research grants.

Key Points: 
  • The scholarship recipients, who both do research at the University of Gothenburg, are rewarded with SEK 100,000 each, which is paid to the Sahlgrenska Academy at the University of Gothenburg as extra research grants.
  • The research shows differences in the physiological effects of different PI3K isoforms, as well as factors that can influence treatment with PI3K-inhibiting substances.
  • Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions.
  • The Volvo Group is headquartered in Gothenburg, Sweden, employs almost 95,000 people and serves customers in more than 190 markets.